Related Experiment Video
Updated: Oct 20, 2025
08:27
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
6.3K
Glucocerebrosidase dysfunction in neurodegenerative disease
Sarah M Brooker1, Dimitri Krainc1
1Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.
Essays in Biochemistry
|September 16, 2021
Summary
The GBA1 gene, linked to Parkinson's disease (PD), impacts β-glucocerebrosidase (GCase) activity. Reduced GCase function creates a feedback loop, worsening α-synuclein (aSyn) buildup and neurodegeneration.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Synucleinopathies, including Parkinson's disease (PD), are defined by α-synuclein (aSyn) aggregate accumulation and neuronal loss.
- The GBA1 gene, encoding β-glucocerebrosidase (GCase), is the primary genetic risk factor for PD and dementia with Lewy bodies (DLB).
Purpose of the Study:
- To review the role of GCase in neuronal function and neurodegenerative disease pathogenesis.
- To explore the therapeutic potential of targeting GCase for synucleinopathies.
Main Methods:
- Literature review of studies on GBA1 mutations, GCase activity, and aSyn pathology.
- Analysis of the relationship between GCase dysfunction and lysosomal/mitochondrial pathways.
Main Results:
- Loss of GCase enzymatic activity contributes to lysosomal and mitochondrial dysfunction.
- A bidirectional relationship exists between GCase and aSyn, forming a pathogenic feedback loop.
- GCase alterations are linked to multiple neurodegenerative pathways.
Conclusions:
- GCase plays a critical role in neuronal health and is implicated in PD and DLB pathogenesis.
- Targeting GCase represents a promising therapeutic strategy for synucleinopathies.
Related Concept Videos
01:26Alzheimer's Disease: Overview
763
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
763
01:22Lysosomal Hydrolases
4.0K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.0K
01:15Parkinson's Disease: Overview
854
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
854
01:22Alzheimer's Disease: Treatment
302
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302
01:37Neural Regulation
40.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.6K
01:32Export of Misfolded Proteins out of the ER
4.2K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
4.2K